Cargando…

Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study

BACKGROUND: This study evaluates the effect of enhanced recovery after surgery (ERAS) pathways on postoperative outcomes of non-small cell lung cancer (NSCLC) patients undergoing video-assisted thoracic surgery (VATS) lobectomy. METHODS: We retrospectively reviewed all consecutive patients undergoin...

Descripción completa

Detalles Bibliográficos
Autores principales: Forster, Céline, Doucet, Valérie, Perentes, Jean Yannis, Abdelnour-Berchtold, Etienne, Zellweger, Matthieu, Faouzi, Mohamed, Bouchaab, Hasna, Peters, Solange, Marcucci, Carlo, Krueger, Thorsten, Rosner, Lorenzo, Gonzalez, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867780/
https://www.ncbi.nlm.nih.gov/pubmed/33569296
http://dx.doi.org/10.21037/tlcr-20-891
_version_ 1783648340918927360
author Forster, Céline
Doucet, Valérie
Perentes, Jean Yannis
Abdelnour-Berchtold, Etienne
Zellweger, Matthieu
Faouzi, Mohamed
Bouchaab, Hasna
Peters, Solange
Marcucci, Carlo
Krueger, Thorsten
Rosner, Lorenzo
Gonzalez, Michel
author_facet Forster, Céline
Doucet, Valérie
Perentes, Jean Yannis
Abdelnour-Berchtold, Etienne
Zellweger, Matthieu
Faouzi, Mohamed
Bouchaab, Hasna
Peters, Solange
Marcucci, Carlo
Krueger, Thorsten
Rosner, Lorenzo
Gonzalez, Michel
author_sort Forster, Céline
collection PubMed
description BACKGROUND: This study evaluates the effect of enhanced recovery after surgery (ERAS) pathways on postoperative outcomes of non-small cell lung cancer (NSCLC) patients undergoing video-assisted thoracic surgery (VATS) lobectomy. METHODS: We retrospectively reviewed all consecutive patients undergoing VATS lobectomy for NSCLC between January 2014 and October 2019 and assigned them to the relevant group (“pre-ERAS” or “ERAS”). Length of stay, readmissions and complications within 30 days were compared between both groups. A propensity score-matched analysis was performed based on sex, age, type of operation, comorbidities, American Society of Anesthesiologists (ASA) score and preoperative pulmonary functions. RESULTS: A total of 307 records (164 male/143 female; 140 ERAS/167 pre-ERAS; median age: 67) were reviewed. There was no statistical difference in patient’s characteristics. Overall ERAS compliance was 81%. The ERAS group presented significantly shorter length of stay (median 5 vs. 7 days; P=0.004) without significant difference in cardiopulmonary complication rate (27.1% vs. 35.9%; P=0.1). Readmission (3.6% vs. 5.4%; P=0.75) and duration of drainage (median 2 vs. 3 days; P=0.14) were similar between groups. The propensity score-matched analysis showed that the length of hospital stay was reduced by 1.4 days (P=0.034) and the postoperative cardiopulmonary complication rate by 13% (P=0.044) in the ERAS group. CONCLUSIONS: Adoption of an ERAS pathway for VATS lobectomies in NSCLC patients has decreased the length of hospital stay and the cardiopulmonary complication rate without affecting the readmission rate.
format Online
Article
Text
id pubmed-7867780
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-78677802021-02-09 Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study Forster, Céline Doucet, Valérie Perentes, Jean Yannis Abdelnour-Berchtold, Etienne Zellweger, Matthieu Faouzi, Mohamed Bouchaab, Hasna Peters, Solange Marcucci, Carlo Krueger, Thorsten Rosner, Lorenzo Gonzalez, Michel Transl Lung Cancer Res Original Article BACKGROUND: This study evaluates the effect of enhanced recovery after surgery (ERAS) pathways on postoperative outcomes of non-small cell lung cancer (NSCLC) patients undergoing video-assisted thoracic surgery (VATS) lobectomy. METHODS: We retrospectively reviewed all consecutive patients undergoing VATS lobectomy for NSCLC between January 2014 and October 2019 and assigned them to the relevant group (“pre-ERAS” or “ERAS”). Length of stay, readmissions and complications within 30 days were compared between both groups. A propensity score-matched analysis was performed based on sex, age, type of operation, comorbidities, American Society of Anesthesiologists (ASA) score and preoperative pulmonary functions. RESULTS: A total of 307 records (164 male/143 female; 140 ERAS/167 pre-ERAS; median age: 67) were reviewed. There was no statistical difference in patient’s characteristics. Overall ERAS compliance was 81%. The ERAS group presented significantly shorter length of stay (median 5 vs. 7 days; P=0.004) without significant difference in cardiopulmonary complication rate (27.1% vs. 35.9%; P=0.1). Readmission (3.6% vs. 5.4%; P=0.75) and duration of drainage (median 2 vs. 3 days; P=0.14) were similar between groups. The propensity score-matched analysis showed that the length of hospital stay was reduced by 1.4 days (P=0.034) and the postoperative cardiopulmonary complication rate by 13% (P=0.044) in the ERAS group. CONCLUSIONS: Adoption of an ERAS pathway for VATS lobectomies in NSCLC patients has decreased the length of hospital stay and the cardiopulmonary complication rate without affecting the readmission rate. AME Publishing Company 2021-01 /pmc/articles/PMC7867780/ /pubmed/33569296 http://dx.doi.org/10.21037/tlcr-20-891 Text en 2021 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Forster, Céline
Doucet, Valérie
Perentes, Jean Yannis
Abdelnour-Berchtold, Etienne
Zellweger, Matthieu
Faouzi, Mohamed
Bouchaab, Hasna
Peters, Solange
Marcucci, Carlo
Krueger, Thorsten
Rosner, Lorenzo
Gonzalez, Michel
Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
title Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
title_full Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
title_fullStr Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
title_full_unstemmed Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
title_short Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
title_sort impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867780/
https://www.ncbi.nlm.nih.gov/pubmed/33569296
http://dx.doi.org/10.21037/tlcr-20-891
work_keys_str_mv AT forsterceline impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT doucetvalerie impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT perentesjeanyannis impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT abdelnourberchtoldetienne impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT zellwegermatthieu impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT faouzimohamed impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT bouchaabhasna impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT peterssolange impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT marcuccicarlo impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT kruegerthorsten impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT rosnerlorenzo impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy
AT gonzalezmichel impactofanenhancedrecoveryaftersurgerypathwayonthoracoscopiclobectomyoutcomesinnonsmallcelllungcancerpatientsapropensityscorematchedstudy